The list below, as well as information from Daiichi Sankyo Group-sponsored clinical trials registered and published on registries such as ClinicalTrials.gov, EU Clinical Trials Register and Japan Registry of Clinical Trials (jRCT), are provided for informational purposes only, and are not intended to promote any product. Clinical study reports provide results known at the time of the study completion and analysis. Therefore, the results provided may not provide either a complete or current review of the safety and efficacy of the pharmaceutical product studied.
  Health care providers and patients should refer to the current product labeling for detailed information on approved indications in their country or region.
  This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medication is the correct or best treatment option for a particular patient. If you have questions, please consult with a health care professional.



Search by Disease Name, Project Code, Generic Name or Study Code


A

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Azelnidipine CALBLOCK® Hypertension CB502-021 jRCT1080220028
JapicCTI-050028
AC430 Discontinued Healthy Subjects AC430-001 NCT01287858
AC480IV Discontinued Advanced Solid Cancer AC480IV-001 NCT01245543
ASB17061 Discontinued Atopic Dermatitis ASBI 704 NCT01756898 Tabulated Results
(CT.gov)

B

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Bempedoic Acid N/A Primary Hypercholestero
lemia;
Mixed Dyslipidemia
DSE-BMP-01-22-EU NCT05798390
Baclofen GABALON® Spastic Paralysis DL404-02P jRCT1080220031
JapicCTI-050031
Summary Results
(jRCT)
Baclofen GABALON® Spastic Paralysis DL404-01 jRCT2080220061
JapicCTI-050061

C

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
COVID-19 mRNA Vaccine
(DS-5670)
DAICHIRONA® Prevention of Infectious Disease by SARS-CoV-2 DS5670-238 jRCT2031230423
COVID-19 mRNA Vaccine
(DS-5670)
DAICHIRONA® Prevention of Infectious Disease by SARS-CoV-2 DS5670-237 jRCT2031230424
COVID-19 mRNA Vaccine
(DS-5670)
DAICHIRONA® Prevention of Infectious Disease by SARS-CoV-2 DS5670-214 jRCT2031220665
COVID-19 mRNA Vaccine
(DS-5670)
DAICHIRONA® Prevention of Infectious Disease by SARS-CoV-2 DS5670-212 jRCT2071220111
COVID-19 mRNA Vaccine
(DS-5670)
DAICHIRONA® Prevention of Infectious Disease by SARS-CoV-2 DS5670-203 jRCT2031220399
COVID-19 mRNA Vaccine
(DS-5670)
DAICHIRONA® Prevention of Infectious Disease by SARS-CoV-2 DS5670-202 jRCT2031220400
COVID-19 mRNA Vaccine
(DS-5670)
DAICHIRONA® Prevention of Infectious Disease by SARS-CoV-2 DS5670-103 jRCT2031220264
COVID-19 mRNA Vaccine
(DS-5670)
DAICHIRONA® Prevention of Infectious Disease by SARS-CoV-2 DS5670-146 jRCT2071210106
COVID-19 mRNA Vaccine
(DS-5670)
DAICHIRONA® Prevention of Infectious Disease by SARS-CoV-2 DS5670-116 jRCT2071210086
COVID-19 mRNA Vaccine
(DS-5670)
DAICHIRONA® Prevention of Infectious Disease by SARS-CoV-2 DS5670-A-J101 NCT04821674
jRCT2071200110
Carperitide HANP® Congestive Heart Failure; Myocardiopathies 03-0-162 NCT00259038
Carvedilol ARTIST® Atrial Fibrillation DQ2466-A-J301 jRCT2080222155
JapicCTI-132201
Colesevelam WELCHOL® Pediatric Type 2 Diabetes Mellitus WEL-A-U307 NCT01258075 Tabulated Results
(CT.gov)
Colesevelam WELCHOL® Type 2 Diabetes Mellitus WEL-A-U306 NCT00789750 Tabulated Results
(CT.gov)
Colesevelam WELCHOL® Type 2 Diabetes Mellitus WEL-305 NCT00789737 Tabulated Results
(CT.gov)
Colesevelam WELCHOL® Hyper-cholesterolemia WEL-407 NCT00755352
Colesevelam WELCHOL® Hyper-cholesterolemia WEL-406 NCT00754507
Colesevelam WELCHOL® Hyper-cholesterolemia; Hyperlipidemia, Familial Combined WEL-403 NCT00754039
Colesevelam WELCHOL® Hyper-cholesterolemia WEL-405 NCT00753779
Colesevelam WELCHOL® Type 2 Diabetes Mellitus; Hyper-cholesterolemia; Pre-diabetes WEL-411 NCT00570739 Tabulated Results
(CT.gov)
Colesevelam WELCHOL® Type 2 Diabetes Mellitus WEL-409 NCT00484419 Tabulated Results
(CT.gov)
Colesevelam WELCHOL® Type 2 Diabetes Mellitus WEL-202 NCT00361153
Colesevelam WELCHOL® Hyper-cholesterolemia WEL-408 NCT00185107
Colesevelam WELCHOL® Type 2 Diabetes Mellitus WEL-304 NCT00151762
Colesevelam WELCHOL® Type 2 Diabetes Mellitus WEL-302 NCT00151749
Colesevelam WELCHOL® Type 2 Diabetes Mellitus WEL-303 NCT00147758
Colesevelam WELCHOL® Type 2 Diabetes Mellitus WEL-201 NCT00147745 Tabulated Results
(CT.gov)
Colesevelam WELCHOL® Type 2 Diabetes Mellitus WEL-301 NCT00147719
Colesevelam WELCHOL® Hyper-cholesterolemia WEL-410 NCT00145574
2005-003511-75
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Cevimeline EVOXAC® Xerostomia CDR0000068698 NCT00017511
CS-0777 Discontinued Multiple Sclerosis CS0777-A-U102 NCT00616733
CS-1036 Discontinued Diabetes CS1036-A-A201 jRCT2080221036
JapicCTI-101069
CS-1036 Discontinued Diabetes CS1036-A-J202 jRCT2080221087
JapicCTI-101121
CS-4771 Discontinued Healthy Subjects CS4771-A-J105 jRCT2080221894
JapicCTI-121939
CS-801 Discontinued Overactive Bladder 150-010 jRCT2080220025
JapicCTI-050025
CS-801 Discontinued Overactive Bladder 150-006 jRCT2080220026
JapicCTI-050026
CS-8080 Discontinued Healthy Subjects CS8080-A-U102 NCT00796575
CS-8080 Discontinued Healthy Subjects CS8080-A-U101 NCT00613431
CS-917 Discontinued Type 2 Diabetes Mellitus CS0917-A-U205 NCT00290940
CS-917 Discontinued Type 2 Diabetes Mellitus CS0917-A-E-107 2004-003195-11 Summary Results
(EU-CTIS)

D

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Datopotamab Deruxtecan
(DS-1062)
Non-small Cell Lung Cancer TROPION-Lung07
DS1062-A-U303
NCT05555732
2022-500802-16
jRCT2061220066
Datopotamab Deruxtecan
(DS-1062)
Non-small Cell Lung Cancer TROPION-Lung08
DS1062-A-U304
NCT05215340
jRCT2061210074
2021-002555-10
Datopotamab Deruxtecan
(DS-1062)
Non-small Cell Lung Cancer TROPION-Lung01
DS1062-A-U301
NCT04656652
2020-004643-80
jRCT2071200104
Datopotamab Deruxtecan
(DS-1062)
Non-small Cell Lung Cancer TROPION-Lung02
DS1062-A-U102
NCT04526691
jRCT2031200193
Datopotamab Deruxtecan
(DS-1062)
Non-small Cell Lung Cancer TROPION-Lung05
DS1062-A-U202
NCT04484142
2020-002774-27
jRCT2041200097
Datopotamab Deruxtecan
(DS-1062)
Solid Cancer; Non-Small-Cell Lung Cancer; Triple Negative Breast Cancer TROPION-PanTumor01
DS1062-A-J101
NCT03401385
jRCT2080223756
JapicCTI-173812
DS-1001 Glioma DS1001-A-J201 NCT04458272
jRCT2080225243
JapicCTI-205339
DS-1001 Glioma DS1001-A-J101 NCT03030066
jRCT2080223424
JapicCTI-163479
DS-1055 Head and Neck Cancer; Gastric Cancer; Esophageal Cancer; Other Types of Solid Cancer DS1055-A-J101 NCT04419532
jRCT2080225196
JapicCTI-205292
DS-1103 Advanced Solid Tumor; Breast Cancer DS1103-074 NCT05765851
DS-1211 Pseudoxanthoma Elasticum DS1211-A-U201 NCT05569252
DS-1211 Pseudoxanthoma Elasticum DS1211-A-U104 NCT05025722
DS-1471 Advanced or Metastatic Solid Tumors DS1471-079 NCT06074705
jRCT2031230234
DS-2325 Netherton Syndrome DS2325-119 NCT05979831
2022-502853-32
DS-2325 Netherton Syndrome DS2325-106 NCT05583669
DS-2325 Netherton Syndrome DS2325-104 NCT05388903
DS-3939 Advanced Solid Tumor; Metastatic Solid Tumor DS3939-077 NCT05875168
jRCT2031230233
DS-7011 Systemic Lupus Erythematosus; Cutaneous Lupus Erythematosus DS7011-107 NCT05638802
jRCT2031230588
DS-7011 Healthy Subjects DS7011-A-U101 NCT05203692
DS-7830 Healthy Subjects DS7830-131 jRCT2051230152
DS-9606 Ovarian Cancer; Germ Cell Tumor; Advanced Solid Tumors DS9606-137 NCT05394675
2022-000120-38
Denosumab PRALIA® Rheumatoid Arthritis AMG162-D-J301 NCT01973569
jRCT2080222228
JapicCTI-132277
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Denosumab RANMARK® Giant Cell Tumor of Bone AMG162-B-J201 jRCT2080221624
JapicCTI-111665
Denosumab PRALIA® Rheumatoid Arthritis AMG162-D-J201 jRCT2080221226
JapicCTI-101263
Summary Results
(jRCT)
Denosumab PRALIA® Osteoporosis AMG162-A-J301 NCT00680953
jRCT2080220769
JapicCTI-090797
Tabulated Results
(CT.gov)
Diphtheria Pertussis Tetanus Combined Vaccine Adsorbed Diphtheria-purified Pertussis-tetanus Combined Vaccine  Prevention of Diphtheria; Tetanus; Pertussis VN0103-A-J301 jRCT2080222484
JapicCTI-142535
DS-1205 Out-licensed Non-small Cell Lung Cancer DS1205-A-J102 NCT03599518
jRCT2080223968
JapicCTI-184026
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
DS-1205 Out-licensed Non-small Cell Lung Cancer DS1205-A-U101 NCT03255083
2017-000542-21
Tabulated Results
(CT.gov)
DS-6051 Out-licensed Advanced Solid Malignant Tumors DS6051-A-J102 NCT02675491
jRCT2080223057
JapicCTI-153111
DJ-927 Discontinued Colorectal Cancer CDR0000356034 NCT00080834
DJ-927 Discontinued Solid Cancer CDR0000346368 NCT00077077
DJ-927 Discontinued Non-small Cell Lung Cancer 927E-PRT007 2004-000696-34 Summary Results
(EU-CTIS)
DS-1040 Discontinued Acute Ischemic Stroke DS1040-A-U103 NCT02586233
2015-001824-43
Tabulated Results
(CT.gov)
DS-1040 Discontinued Acute Submassive Pulmonary Embolism DS1040-B-U107 NCT02923115
2015-005211-32
Tabulated Results
(CT.gov)
DS-1040 Discontinued Acute Ischemic Stroke DS1040-A-J110 NCT03198715
jRCT2080223556
JapicCTI-173612
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
DS-1040 Discontinued Healthy Subjects DS1040-A-E108 NCT02647307
2015-003470-32
DS-1040 Discontinued Healthy Subjects DS1040-A-E106 NCT02560688
2015-003018-26
DS-1040 Discontinued Acute Ischemic Stroke DS1040-A-E102 NCT02071004
DS-1093 Discontinued Healthy Subjects DS1093-A-E102 NCT02142400
2014-000552-28
DS-1093 Discontinued Kidney Disease DS1093-A-E103 NCT02299661
2014-002331-33
DS-1123 Discontinued Advanced Solid Tumours DS1123-A-J101 NCT02690337
jRCT2080223031
JapicCTI-153085
DS-1150 Discontinued Type 2 Diabetes Mellitus DS1150-A-U101 NCT02004678
DS-1971 Discontinued Healthy Subjects DS1971-A-E106 NCT02564861
2015-002885-22
DS-1971 Discontinued Type 2 Diabetes Mellitus; Neuropathic Pain DS1971-A-U202 NCT02673866
DS-1971 Discontinued Healthy Subjects DS1971-A-E105 NCT02473627
2015-000330-30
DS-1971 Discontinued Pain DS1971-A-J201 jRCT2080223138
JapicCTI-163193
DS-1971 Discontinued Healthy Subjects DS1971-A-E104 NCT02266940
2014-003662-24
DS-1971 Discontinued Healthy Subjects DS1971-A-E103 NCT02261376
2014-003019-13
DS-1971 Discontinued Healthy Subjects DS1971-A-E102 NCT02190058
2014-001800-23
DS-1971 Discontinued Healthy Subjects DS1971-A-E101 NCT02107885
2014-000240-15
DS-2248 Discontinued Solid Cancer DS2248-A-U101 NCT01288430
2011-002666-21
Tabulated Results
(CT.gov)
DS-2330 Discontinued Chronic Hemodialysis DS2330-A-U103 NCT03305471
DS-2741 Discontinued Atopic Dermatitis;
Healthy Subjects
DS2741-A-J101 NCT04211415
jRCT2080224983
JapicCTI-195071
DS-3078 Discontinued Solid Cancer; Lymphomas DS3078-A-U101 NCT01588678
2011-005988-24
DS-5573 Discontinued Advanced Solid Malignant Tumors DS5573-A-J101 NCT02192567
jRCT2080222535
JapicCTI-142586
DS-6016 Discontinued Healthy Subjects DS6016-A-J101 NCT04818398
jRCT2051200155
DS-6157 Discontinued Gastrointestinal Stromal Tumor DS6157-A-U101 NCT04276415
jRCT2080225089
JapicCTI-205184
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
DS-7080 Discontinued Macular Degeneration DS7080-A-U101 NCT02530918
DS-7250 Discontinued Diabetes DS7250-A-J201 jRCT2080221918
JapicCTI-121963
DS-7309 Discontinued Type 2 Diabetes Mellitus DS7309-A-U102 NCT01956305
DS-7309 Discontinued Type 2 Diabetes Mellitus DS7309-A-U101 NCT01862939
DS-7423 Discontinued Solid Cancer; Colorectal Cancer; Endometrial Cancer DS7423-A-U101 NCT01364844
DS-7423 Discontinued Solid Cancer DS7423-A-J102 jRCT2080221724
JapicCTI-121766
DS-8273 Discontinued Advanced Colorectal Cancer DS8273-A-U103 NCT02991196
DS-8273 Discontinued Advanced Solid Cancer; Lymphomas DS8273-A-U101 NCT02076451
DS-8500 Discontinued Type 2 Diabetes Mellitus DS8500-A-J204 NCT02685345
jRCT2080223082
JapicCTI-163136
DS-8500 Discontinued Hepatic or Renal Impairment DS8500-A-J107 jRCT2080223081
JapicCTI-163135
DS-8500 Discontinued Type 2 Diabetes Mellitus DS8500-A-J205 NCT02669732
jRCT2080223072
JapicCTI-163126
DS-8500 Discontinued Type 2 Diabetes Mellitus DS8500-A-J203 NCT02628392
jRCT2080223014
JapicCTI-153068
DS-8500 Discontinued Type 2 Diabetes Mellitus DS8500-A-U202 NCT02647320 Tabulated Results
(CT.gov)
DS-8500 Discontinued Type 2 Diabetes Mellitus DS8500-A-J201 NCT02222350
jRCT2080222546
JapicCTI-142597
DS-8500 Discontinued Healthy Subjects DS8500-A-J103 jRCT2080223495
JapicCTI-173550
DS-8500 Discontinued Healthy Subjects DS8500-A-J108 jRCT2080223178
JapicCTI-163233
DS-8500 Discontinued Healthy Subjects DS8500-A-J110 jRCT2080223244
JapicCTI-163299
DS-8500 Discontinued Healthy Subjects DS8500-A-U105 NCT03699774
DS-8500 Discontinued Healthy Subjects DS8500-A-U112 NCT02790684
DS-8500 Discontinued Healthy Subjects DS8500-A-U109 NCT02790671
DS-8500 Discontinued Healthy Subjects DS8500-A-J106 jRCT2080222826
JapicCTI-152878
DS-8500 Discontinued Healthy Subjects DS8500-A-J104 jRCT2080222622
JapicCTI-142673
DS-8895 Discontinued Advanced Solid Cancer DS8895-A-J101 NCT02004717
jRCT2080222257
JapicCTI-132306
DS-9231 (TS23) Discontinued Acute Pulmonary Embolism DS9231-A-U201 2017-000552-25

E

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation LIX-OS-22-01 NCT05804747
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation EDX/18/0414(2) NCT05262322
Edoxaban SAVAYSA®; LIXIANA® Non-valvular Atrial Fibrillation DSCN-ETNA AF-RWS-001 NCT04747496
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation ETAF-TR-01 NCT04594915
Edoxaban SAVAYSA®; LIXIANA® Non-valvular Atrial Fibrillation DS-EDO-01-20-DE NCT04519944
Edoxaban SAVAYSA®; LIXIANA® Cardiac Disease DU176b-C-U313 NCT03395639
2017-000475-90
Tabulated Results
(CT.gov)
(EU-CTIS)
Plain Language Summary
(EN)
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-C-A4012 NCT03247582
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-C-A4011 NCT03247569
Edoxaban SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-D-A4010 NCT02952599
Edoxaban SAVAYSA®; LIXIANA® Non-Valvular Atrial Fibrillation DU176b-C-A4008 NCT02951039
Edoxaban SAVAYSA®; LIXIANA® Non-Valvular Atrial Fibrillation DU176B-C-U4001 NCT02943785
2016-003930-26
Tabulated Results
(CT.gov)
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation; Venous Thromboembolism DSE-EDO-02-15-EU NCT02950168
Edoxaban SAVAYSA®; LIXIANA® Non-Valvular Atrial Fibrillation DU176b-C-E314 NCT02964949
2016-001795-30
Tabulated Results
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Venous Thromboembolism DSE-EDO-05-14-EU NCT02943993 Tabulated Results
(CT.gov)
Edoxaban SAVAYSA®; LIXIANA® Non Valvular Atrial Fibrillation DSE-EDO-04-14-EU NCT02944019
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation DSE-EDO-01-16-EU NCT02942576
2016-003069-25
Tabulated Results
(CT.gov)
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Non-Valvular Atrial Fibrillation DSE-EDO-01-15-EU NCT02866175
2016-002683-14
Tabulated Results
(CT.gov)
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Non-valvular Atrial Fibrillation DU176b-C-J316 NCT02801669
jRCT2080223211
JapicCTI-163266
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Edoxaban SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-D-U312 NCT02798471
2016-000991-49
Tabulated Results
(CT.gov)
(EU-CTIS)
Plain Language Summary
(EN)
Edoxaban SAVAYSA®; LIXIANA® Deep Vein Thrombosis; Venous Thromboembolism DU176b-A-U157 NCT02303431
2015-005732-18
Tabulated Results
(CT.gov)
Edoxaban SAVAYSA®; LIXIANA® Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Cancer DU176b-D-U311 NCT02073682
2014-004708-30
Tabulated Results
(CT.gov)
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-F-E308 NCT02072434
2013-003148-21
Tabulated Results
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Peripheral Arterial Disease DU176b-E-U210 NCT01802775
2012-003009-88
Tabulated Results
(CT.gov)
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Non-valvular Atrial Fibrillation DU176b-C-J307 jRCT2080221674
JapicCTI-111716
Summary Results
(jRCT)
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-B-J307 NCT01857622 Tabulated Results
(CT.gov)
Edoxaban SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-B-J306 NCT01857583 Tabulated Results
(CT.gov)
Edoxaban SAVAYSA®; LIXIANA® Non-Valvular Atrial Fibrillation DU176b-D-U211 NCT01662908 Tabulated Results
(CT.gov)
Edoxaban SAVAYSA®; LIXIANA® Venous Thromboembolism; Thromboembolism; Thrombosis; Deep Vein Thrombosis; Arthroplasty; Hip Replacement DU176b-B-J209 NCT01203098
jRCT2080220798
JapicCTI-090827
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Edoxaban SAVAYSA®; LIXIANA® Deep-Vein Blood Clots; Lung Blood Clots DU176b-D-U305 NCT00986154
2009-014290-40
jRCT2080221010
JapicCTI-101043
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-B-J304 NCT01181167
jRCT2080220743
JapicCTI-090771
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Edoxaban SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-B-J303 NCT01181141
jRCT2080220770
JapicCTI-090798
Tabulated Results
(CT.gov)
Edoxaban SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-B-J302 NCT01181102
jRCT2080220701
JapicCTI-090727
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-C-U301 NCT00781391
2008-004522-16
jRCT2080220747
JapicCTI-090775
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-C-J225 NCT00829933
jRCT2080220382
JapicCTI-070391
Tabulated Results
(CT.gov)
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-C-J226 NCT00806624 Tabulated Results
(CT.gov)
Edoxaban SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-04 NCT01203072
jRCT2080220278
JapicCTI-060283
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Edoxaban SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-PRT018 NCT00504556
2007-001271-11
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Thrombosis; Hip Replacement DU176b-PRT011 NCT00398216
2006-000758-29
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Arthroplasty, Hip Replacement; Thrombosis DU176b-PRT007 NCT00107900
2004-004415-29
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Edoxaban SAVAYSA®; LIXIANA® Healthy Subjects DU176b-A-U158 NCT02047565
Esaxerenone MINNEBRO® Type 2 Diabetes CS3150-B-J309 jRCT2080223640
JapicCTI-173696
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Type 2 Diabetes CS3150-B-J308 jRCT2080223639
JapicCTI-173695
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Type 2 Diabetes Mellitus CS3150-B-J204 NCT02345057
jRCT2080222722
JapicCTI-152774
Esaxerenone MINNEBRO® Diabetes CS3150-B-J202 jRCT2080221972
JapicCTI-122018
Esaxerenone MINNEBRO® Primary Aldosteronism CS3150-A-J307 NCT02885662
jRCT2080223294
JapicCTI-163349
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Essential Hypertension CS3150-A-J303 NCT02848170
jRCT2080223269
JapicCTI-163324
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Hypertension With Type 2 Diabetes and Albuminuria CS3150-A-J306 NCT02807974
jRCT2080223238
JapicCTI-163293
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Severe Hypertension CS3150-A-J304 NCT02808026
jRCT2080223232
JapicCTI-163287
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Moderate Renal Impairment; Hypertension CS3150-A-J305 NCT02807987
jRCT2080223233
JapicCTI-163288
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Essential Hypertension CS3150-A-J301 NCT02890173
jRCT2080223293
JapicCTI-163348
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Essential Hypertension CS3150-A-J302 NCT02722265
jRCT2080223121
JapicCTI-163176
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Hypertension; Moderate Renal Impairment CS3150-A-J206 NCT02448628
jRCT2080222831
JapicCTI-152883
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Hypertension CS3150-A-J203 NCT02345044
jRCT2080222720
JapicCTI-152772
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Hypertension CS3150-A-J201 jRCT2080221876
JapicCTI-121921
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Healthy Subjects CS3150-C-J101 jRCT1080224760
JapicCTI-194837
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Healthy Subjects CS3150-A-J112 jRCT2080223397
JapicCTI-163452
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Healthy Subjects CS3150-A-J111 jRCT2080223388
JapicCTI-163443
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Healthy Subjects CS3150-A-J110 jRCT2080223324
JapicCTI-163379
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Hepatic Impairment CS3150-A-J109 jRCT2080223284
JapicCTI-163339
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Healthy Subjects CS3150-A-J108 jRCT2080223231
JapicCTI-163286
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Healthy Subjects CS3150-A-J107 jRCT2080222780
JapicCTI-152832
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Healthy Subjects CS3150-A-U106 NCT04019652
Esaxerenone MINNEBRO® Healthy Subjects CS3150-A-J102 jRCT2080223421
JapicCTI-163476
Summary Results
(jRCT)
Esaxerenone MINNEBRO® Healthy Subjects CS3150-A-J101 jRCT2080223418
JapicCTI-163473
Summary Results
(jRCT)
Efatutazone Discontinued Colorectal Cancer CS7017-A-J111 jRCT2080221193
JapicCTI-101230
Efatutazone Discontinued Non-Smal Cell Lung Cancer CS7017-A-A110 NCT01199068 Tabulated Results
(CT.gov)
Efatutazone Discontinued Non-Smal Cell Lung Cancer CS7017-A-A108 NCT01199055 Tabulated Results
(CT.gov)
Efatutazone Discontinued Solid Cancer CS7017-A-J107 jRCT2080220936
JapicCTI-090968
Efatutazone Discontinued Lung Cancer CS7017-A-U204 NCT01101334
2009-016083-36
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Efatutazone Discontinued Colorectal Cancer CS7017-A-E201 NCT00986440
2008-005848-16
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Efatutazone Discontinued Colorectal Cancer CS7017-A-U203 NCT00967616 Tabulated Results
(CT.gov)
Efatutazone Discontinued Cancer CS7017-A-U102E NCT00881569 Tabulated Results
(CT.gov)
Efatutazone Discontinued Lung Cancer CS7017-A-U202 NCT00806286
2009-013428-22
Tabulated Results
(CT.gov)
Efatutazone Discontinued Anaplastic Thyroid Cancer CS7017-A-U103 NCT00603941 Tabulated Results
(CT.gov)
Efatutazone Discontinued Neoplasm CS7017-A-U102 NCT00408434 Tabulated Results
(CT.gov)
Exatecan Discontinued Sarcoma CDR0000271889 NCT00055952
Exatecan Discontinued Sarcoma CDR0000271888 NCT00055939
Exatecan Discontinued Pancreatic Cancer CDR0000068880 NCT00023972
Exatecan Discontinued Esophageal Cancer; Gastric Cancer CDR0000068663 NCT00017212
Exatecan Discontinued Biliary Cancer CDR0000067736 NCT00005938
Exatecan Discontinued Cervical Cancer CDR0000067525 NCT00004866
Exatecan Discontinued Brain and Central Nervous System Cancer; Lymphoma; Unspecified Childhood Solid Cancer CDR0000067330 NCT00004212
Exatecan Discontinued Liver Cancer CDR0000067329 NCT00004108
Exatecan Discontinued Ovarian, Fallopian Tube, or Peritoneal Cancer CDR0000067258 NCT00004060
Exatecan Discontinued Hematologic Cancer CDR0000067149 NCT00004047
Exatecan Discontinued Breast Cancer CDR0000067148 NCT00004046
Exatecan Discontinued Prostate Cancer CDR0000067146 NCT00004045
Exatecan Discontinued Pancreatic cancer CDR0000067147 NCT00003951

G

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Ghrelin Discontinued Anorexia SUN11031 (NA3801) jRCT2080220697
JapicCTI-090723
Ghrelin Discontinued Chronic Obstructive Pulmonary Disease ASBI 307 NCT00698828
2007-007725-46
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)

H

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Hydromorphone NARUVEIN® Cancer Pain DS7113-C-J306 jRCT2080222685
JapicCTI-142736
Summary Results
(jRCT)
Hydromorphone NARUVEIN® Cancer Pain DS7113-C-J305 jRCT2080222684
JapicCTI-142735
Summary Results
(jRCT)
Hydromorphone NARUSUS® Cancer Pain DS7113-B-J304 jRCT2080222616
JapicCTI-142667
Summary Results
(jRCT)
Hydromorphone NARUSUS® Cancer Pain DS7113-B-J303 jRCT2080222615
JapicCTI-142666
Summary Results
(jRCT)
Hydromorphone NARURAPID® Cancer Pain DS7113-A-J302 jRCT2080222239
JapicCTI-132288
Summary Results
(jRCT)
Hydromorphone NARURAPID® Cancer Pain DS7113-A-J301 jRCT2080222289
JapicCTI-132338
Summary Results
(jRCT)
Hydromorphone NARURAPID® Cancer Pain DS7113-A-J201 jRCT2080222120
JapicCTI-132166
Summary Results
(jRCT)
Hydromorphone NARURAPID®; NARUSUS® Healthy Subjects DS7113-A-J102 jRCT2080222121
JapicCTI-132167

I

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Ifinatamab Deruxtecan
(DS-7300)
Small-cell Lung Cancer IDeate-Lung02
DS7300-188
NCT06203210
jRCT2031230631
Ifinatamab Deruxtecan
(DS-7300)
Small-cell Lung Cancer DS7300-127 NCT05280470
jRCT2041220019
Ifinatamab Deruxtecan
(DS-7300)
Advanced Solid Cancer DS7300-A-J101 NCT04145622
jRCT2080224907
JapicCTI-194992
Influenza Vaccine Intranasal   Prevention of Influenza VN0107-A-J301 jRCT2080223345
JapicCTI-163400
Summary Results
(jRCT)
Plain Language Summary
(JP)
Influenza Vaccine Adsorbed Influenza Vaccine H5N1 Prevention of Influenza KIBPCI-A-J303 jRCT2080222503
JapicCTI-142554
Summary Results
(jRCT)
Influenza Vaccine Adsorbed Influenza Vaccine H5N1 Prevention of Influenza KIBPCI-A-J301 jRCT2080221874
JapicCTI-121919
Summary Results
(jRCT)
Influenza Vaccine Adsorbed Influenza Vaccine H5N1 Prevention of Influenza KIBPCI-A-J302 jRCT2080221923
JapicCTI-121968
Summary Results
(jRCT)
Influenza Vaccine Adsorbed Influenza Vaccine H5N1 Prevention of Influenza KIBPCI-A-J201 jRCT2080222144
JapicCTI-132190
Summary Results
(jRCT)
Influenza Vaccine Influenza HA Vaccine Prevention of Influenza VN0104-A-J201 jRCT2080222536
JapicCTI-142587
Summary Results
(jRCT)
Irinotecan TOPOTECIN® Small Cell Lung Cancer;
Non-small Cell Lung Cancer;
Cervical Cancer;
Ovarian Cancer;
Gastric Cancer
Observational Study jRCT1080220914
JapicCTI-090946
Irinotecan TOPOTECIN® Colorectal Cancer Observational Study jRCT1080220913
JapicCTI-090945
Irinotecan TOPOTECIN® Colorectal Cancer TOP-003 NCT00284258
jRCT1080220199
JapicCTI-060202
Irinotecan TOPOTECIN® Gastric Cancer TOP-002 jRCT1080220081
JapicCTI-050083
Summary Results
(jRCT)
Influenza Vaccine Discontinued Prevention of Influenza VN100-A-J301 jRCT2080222443
JapicCTI-142493
Summary Results
(jRCT)
Influenza Vaccine Discontinued Prevention of Influenza VN100-A-J302 jRCT2080222562
JapicCTI-142613
Summary Results
(jRCT)
Influenza Vaccine Discontinued Prevention of Influenza VN100-A-J303 jRCT2080222939
JapicCTI-152991
Summary Results
(jRCT)
Influenza Vaccine Discontinued Prevention of Influenza VN100-A-J101 jRCT2080222050
JapicCTI-132096
Summary Results
(jRCT)
Ioforminol Discontinued Coronary Angiography GE145-A-J203 jRCT2080222467
JapicCTI-142517
Ioforminol Discontinued Coronary Angiography GE145-A-J202 jRCT2080222468
JapicCTI-142518
Ioforminol Discontinued Coronary Angiography GE145-A-J201 jRCT2080222341
JapicCTI-132391

L

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Laninamivir INAVIR® Influenza CS8958-B-J311 jRCT2080223343
JapicCTI-163398
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza CS8958-B-J310 jRCT2080223342
JapicCTI-163397
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza (Prophylaxis) CS8958-A-J309 jRCT2080222628
JapicCTI-142679
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza (Prophylaxis) CS8958-A-J308 jRCT2080222627
JapicCTI-142678
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza (Prophylaxis) CS8958-A-J307 jRCT2080221607
JapicCTI-111647
Laninamivir INAVIR® Influenza CS8958-A-J306 jRCT2080220909
JapicCTI-090941
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza CS8958-A-J305 jRCT2080220908
JapicCTI-090940
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza CS8958-A-A202 jRCT2080220797
JapicCTI-090826
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza CS8958-A-J304 jRCT2080220785
JapicCTI-090814
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza CS8958-A-J303 jRCT2080220784
JapicCTI-090813
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza CS8958-A-J302 jRCT2080220783
JapicCTI-090812
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza CS8958-A-J301 NCT00803595 Tabulated Results
(CT.gov)
Laninamivir INAVIR® Influenza CS8958-A-J203 jRCT2080220782
JapicCTI-090811
Summary Results
(jRCT)
Laninamivir INAVIR® Influenza CS8958-A-J201 jRCT2080220781
JapicCTI-090810
Summary Results
(jRCT)
Laninamivir INAVIR® Healthy Subjects CS8958-B-J109 jRCT2080222944
JapicCTI-152996
Summary Results
(jRCT)
Laninamivir INAVIR® Healthy Subjects CS8958-A-J108 jRCT2080221402
JapicCTI-111441
Levofloxacin CRAVIT® Infections DR3355-B-J305 jRCT2080221818
JapicCTI-121861
Summary Results
(jRCT)
Levofloxacin CRAVIT® Infections DR3355-B-J304 jRCT2080221853
JapicCTI-121898
Summary Results
(jRCT)
Levofloxacin CRAVIT® Infections DR3355-B-J303 jRCT2080221815
JapicCTI-121858
Summary Results
(jRCT)
Levofloxacin CRAVIT® Infections DR3355-B-J302 jRCT2080221802
JapicCTI-121844
Summary Results
(jRCT)
Levofloxacin CRAVIT® Infections DR3355-B-J301 jRCT2080221777
JapicCTI-121819
Summary Results
(jRCT)
Levofloxacin CRAVIT® Infections DR3355-60 jRCT2080220476
JapicCTI-070486
Summary Results
(jRCT)

M

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
MMR Vaccine Prevention of Measles; Mumps; Rubella VN0102-A-J301 jRCT2080225026
JapicCTI-205118
MMR Vaccine Prevention of Measles; Mumps; Rubella VN0102-A-J302 jRCT2080225025
JapicCTI-205117
MMR Vaccine Prevention of Measles; Mumps; Rubella VN0102-A-J303 jRCT2080225022
JapicCTI-205114
MMR Vaccine Prevention of Measles; Mumps; Rubella JVC-001-P12-01 jRCT2080222978
JapicCTI-153031
Summary Results
(jRCT)
Mirogabalin TARLIGE® Diabetic Peripheral Neuropathic Pain DS5565-A-A315 NCT04094662
Mirogabalin TARLIGE® Central Neuropathic Pain DS5565-A-J314 NCT03901352
jRCT2080224584
JapicCTI-194653
Summary Results
(jRCT)
Mirogabalin TARLIGE® Fibromyalgia DS5565-A-U307 NCT02496884
2014-003972-21
Tabulated Results
(CT.gov)
(EU-CTIS)
Mirogabalin TARLIGE® Fibromyalgia DS5565-A-E309 NCT02146430
2013-005161-40
Tabulated Results
(CT.gov)
(EU-CTIS)
Mirogabalin TARLIGE® Fibromyalgia DS5565-A-E311 NCT02187159
2013-005163-10
Tabulated Results
(CT.gov)
(EU-CTIS)
Mirogabalin TARLIGE® Post-herpetic Neuralgia DS5565-A-J304 NCT02318719
jRCT2080222691
JapicCTI-142742
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Mirogabalin TARLIGE® Renal Impairment; Diabetic Peripheral Neuropathic Pain; Post-herpetic Neuralgia DS5565-A-J313 NCT02607280
jRCT2080223005
JapicCTI-153059
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Mirogabalin TARLIGE® Pain Associated With Fibromyalgia DS5565-A-E310 NCT02187471
2013-005162-20
Tabulated Results
(CT.gov)
(EU-CTIS)
Mirogabalin TARLIGE® Diabetic Peripheral Neuropathic Pain DS5565-A-J303 NCT02318706
jRCT2080222690
JapicCTI-142741
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Mirogabalin TARLIGE® Pain Associated with Fibromyalgia DS5565-A-E312 NCT02234583
2013-005164-26
Tabulated Results
(CT.gov)
(EU-CTIS)
Mirogabalin TARLIGE® Diabetic Peripheral Neuropathy DS5565-A-U201 NCT01496365 Tabulated Results
(CT.gov)
Mirogabalin TARLIGE® Type 2 Diabetes Mellitus; Diabetic Peripheral Neuropathic Pain DS5565-A-J202 NCT01504412
jRCT2080221671
JapicCTI-111713
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Mirogabalin TARLIGE® Renal Dysfunction DS5565-A-J115 jRCT2080222129
JapicCTI-132175
Summary Results
(jRCT)
Mirogabalin TARLIGE® Healthy Subjects DS5565-A-J316 jRCT1080225061
JapicCTI-205156
Mirogabalin TARLIGE® Healthy Subjects DS5565-A-A118 jRCT1080223624
JapicCTI-173680
Summary Results
(jRCT)
Memantine MEMARY® Alzheimer's Disease SUNY7017-A-J301 jRCT2080223154
JapicCTI-163209
Memantine MEMARY® Alzheimer's Disease SUN Y7017 (IE3701) jRCT1080221701
JapicCTI-121743
Summary Results
(jRCT)
Memantine MEMARY® Alzheimer's Disease SUN Y7017 (MA3301) jRCT2080220079
JapicCTI-050079
Summary Results
(jRCT)
Memantine MEMARY® Alzheimer's Disease SUN Y7017 (IE3501) jRCT2080220078
JapicCTI-050078
Summary Results
(jRCT)
Morphine Sulfate MORPHABOND® Baseline Epidemiologic Assessment MORPH-A-U403 NCT04033094
Milademetan Out-licensed Acute Myeloid Leukemia DS3032-A-J104 NCT03671564
jRCT2080223995
JapicCTI-184054
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Milademetan Out-licensed Acute Myeloid Leukemia DS3032-A-U105 NCT03552029 Tabulated Results
(CT.gov)
Milademetan Out-licensed Hematological Malignancies DS3032-A-U102 NCT02319369 Tabulated Results
(CT.gov)
Milademetan Out-licensed Solid Cancer; Lymphomas DS3032-A-J103 jRCT2080222642
JapicCTI-142693
Summary Results
(jRCT)
Milademetan Out-licensed Advanced Solid Cancer; Lymphomas DS3032-A-U101 NCT01877382 Tabulated Results
(CT.gov)
Milademetan Out-licensed Healthy Subjects DS3032-A-U115 NCT03647202
Milademetan Out-licensed Healthy Subjects DS3032-A-U107 NCT03614455

N

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Nafamostat Discontinued Healthy Subjects DS2319-A-J101 jRCT2051200153
Nimotuzumab Discontinued Lung Cancer DE766-A-J303 jRCT2080222038
JapicCTI-132084
Nimotuzumab Discontinued Esophageal Cancer DE766-A-J102 jRCT2080221282
JapicCTI-101319
Nimotuzumab Discontinued Non-small Cell Lung Cancer DE766-A-J202 jRCT2080220796
JapicCTI-090825
Nimotuzumab Discontinued Gastric Cancer DE766-A-J201 jRCT2080220818
JapicCTI-090849

O

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Ofloxacin TARIVID® Infections 8280A-PRT021 NCT00781521
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension CS0866-A-U301 NCT00151775
2015-003329-32
Tabulated Results
(CT.gov)
(EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Metabolic Syndrome; Hypertension DSE-866/47 NCT00676845
2007-003131-23
Summary Results
(EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential
Hypertension; Carotid Plaque
DSE-OLM-01-09 NCT01132768
2009-013342-92
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension 866-447 NCT00185120
Olmesartan Medoxomil BENICAR®; OLMETEC® Metabolic Syndrome; Hypertension DSE-866/46 NCT00891267
2007-003130-41
Summary Results
(EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Diabetic
Nephropathy; Type 2 Diabetes
Mellitus; Proteinuria
149-011/150-008 (ORIENT) NCT00141453
jRCT2080220027
JapicCTI-050027
Tabulated Results
(CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension CS0866-A-U452 NCT00949884 Tabulated Results
(CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Mild to moderate hypertension SP-OLM-03-05 NCT00311155
2005-004659-36
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential Hypertension; Renal Impairment SE-866/43 NCT00151827
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential
Hypertension
SS-866/01 NCT00856271
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential
Hypertension
SS-866 CMB/01 NCT00872586
Olmesartan Medoxomil BENICAR®; OLMETEC® Chronic Glomerulonephritis or Diabetic Nephropathy CS0866-C-J201 NCT00914524
Olmesartan Medoxomil BENICAR®; OLMETEC® Chronic Heart
Failure;
High Blood
B-type (or Brain) Natriuretic
Peptide Level
DSE-866-45 NCT00679484
2007-003060-22
Summary Results
(EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension CS0866-A-U102 NCT00151814
2015-003328-30
Tabulated Results
(CT.gov)
(EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension 866-451 NCT00430638 Tabulated Results
(CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Type 2 Diabetes
Mellitus;
Cardiovascular
Disease; Kidney Disease
SE-866/44 NCT00185159
2004-000506-52
Summary Results
(EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension OLM004-071 NCT00858702 Tabulated Results
(CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension 866-450 NCT00412932 Tabulated Results
(CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension TSP-866/01 NCT00857285 Tabulated Results
(CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential
Hypertension
SPB-OM-0106 NCT00890591 Tabulated Results
(CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension 866-432 NCT00772499
Olmesartan Medoxomil BENICAR®; OLMETEC® Isolated Systolic Hypertension SE-866/37 NCT00751829
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential
Hypertension
SE-866/36 NCT00751751
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential
Hypertension
SP-OLM-01-00 NCT00185172
2005-004659-36
Olmesartan Medoxomil BENICAR®; OLMETEC® Atherosclerosis;
Essential
Hypertension
SE-866/27 NCT00185185
Olmesartan Medoxomil BENICAR®; OLMETEC® Type 2 Diabetes
Mellitus;
Renal Disease
SE-866/29 NCT00362960
Olmesartan Medoxomil BENICAR®; OLMETEC® Atherosclerosis 866-422 AIMS NCT00382213
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential
Hypertension
866-440 NCT00185094
Olmesartan Medoxomil BENICAR®; OLMETEC® Healthy Subjects 866-448 NCT00185055
Olmesartan Medoxomil BENICAR®; OLMETEC® Healthy Subjects CS0866-A-U101 2015-003005-41 Tabulated Results
(EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension OMEGA study jRCT1080220002
JapicCTI-050002

Summary Results
(jRCT)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension PMS-OLM-200801 jRCT1080221127
JapicCTI-101162
Summary Results
(jRCT)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension DSE-SEV-02-09 NCT01101009
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension CS8663-404 NCT00791258 Tabulated Results
(CT.gov)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Type 2 Diabetes
Mellitus;
Hypertension
CS-8663-403 NCT00654745 Tabulated Results
(CT.gov)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension 8663-402 NCT00527514 Tabulated Results
(CT.gov)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension CS8663-A-U301 NCT00185133
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Essential
Hypertension
CS8663-A-E303 NCT00220233
2005-000450-75
Summary Results
(EU-CTIS)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Essential
Hypertension
CS8663-A-E302 NCT00220220
2005-000447-28
Summary Results
(EU-CTIS)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Essential
Hypertension
DSE-SEV-02-09 2009-012966-30 Summary Results
(EU-CTIS)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Healthy Subjects SS8663-03 jRCT2080221540
JapicCTI-111580
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension SS8663-02 jRCT2080221541
JapicCTI-111581
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension SS8663-01 jRCT2080221543
JapicCTI-111583
Olmesartan Medoxomil + Amlodipine + Hydrochloro
thiazide
TRIBENZOR®; SEVIKAR HCT® Essential
Hypertension
CS8635-A-E302 NCT00923091
2008-003534-25
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Olmesartan Medoxomil + Amlodipine + Hydrochloro
thiazide
TRIBENZOR®; SEVIKAR HCT® Essential
Hypertension
CS8635-A-E303 NCT00902538
2008-003535-20
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Olmesartan Medoxomil + Amlodipine + Hydrochloro
thiazide
TRIBENZOR®; SEVIKAR HCT® Hypertension CS8635-A-U301 NCT00649389 Tabulated Results
(CT.gov)
Olmesartan Medoxomil + Amlodipine + Hydrochloro
thiazide
TRIBENZOR®; SEVIKAR HCT® Essential
Hypertension
CS8635-SIT-11-01 NCT01838850
Olmesartan Medoxomil + Azelnidipine REZALTAS® Hypertension CS0866AZ-A-J301 jRCT2080220281
JapicCTI-060286
Summary Results
(jRCT)
Olmesartan Medoxomil + Azelnidipine REZALTAS® Hypertension CS0866AZ-A-J302 jRCT2080220290
JapicCTI-060295
Summary Results
(jRCT)
Olmesartan Medoxomil + Azelnidipine REZALTAS® Hypertension CS0866AZ-A-J303 jRCT2080220439
JapicCTI-070449
Summary Results
(jRCT)
Olmesartan Medoxomil + Hydrochloro
thiazide
BENICAR HCT®; OLMETEC PLUS® Type 2 Diabetes
Mellitus
866-449 NCT00403481 Tabulated Results
(CT.gov)
Olmesartan Medoxomil + Hydrochloro
thiazide
BENICAR HCT®; OLMETEC PLUS® Hypertension CS866CM-B-E301 NCT00430508
2006-003876-37
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Olmesartan Medoxomil + Hydrochloro
thiazide
BENICAR HCT®; OLMETEC PLUS® Essential
Hypertension
CS866CM-B-E302 NCT00430950
2006-003877-28
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Olmesartan Medoxomil; Olmesartan Medoxomil + Hydrochloro
thiazide
BENICAR®; OLMETEC®; BENICAR HCT®; OLMETEC PLUS® Essential
Hypertension
866-443 NCT00185068
Oxycodone OXYCODONE Healthy Subjects DS5058-C-J106 jRCT1080223737
JapicCTI-173793
Summary Results
(jRCT)
Oxycodone OXYCODONE Healthy Subjects DS5058-C-J104 jRCT1080223551
JapicCTI-173606
Summary Results
(jRCT)
Oxycodone OXYCODONE Healthy Subjects DS5058-A-J101 jRCT1080223420
JapicCTI-163475
Summary Results
(jRCT)
Observational Study N/A Hormone-receptor-positive Breast Cancer;
HER2-low Breast Cancer;
HER2-negative Breast Cancer
U31402-0005-NIS-EPI NCT06040593
Observational Study N/A Non-small Cell Lung Cancer U31402-0003-NIS-MA NCT05769764
Observational Study N/A HER2-positive Breast Cancer DSCN-EHT-NIS-BC001 NCT05769751
Observational Study N/A Gastric Cancer DS-ASCAHQ-ENH-GC001 NCT05606094
Observational Study N/A Hyper-
cholesterolemia;
Mixed Dyslipidemia
DSE-BMP-01-20 NCT04579367
Observational Study N/A Hyper-
cholesterolemia;
Mixed Dyslipidemia
SYROS-DSE-BMP-01-21-EU NCT05546398
Observational Study N/A Dyslipidemic; Atherosclerotic Cardiovascular
Disease; Hyper-cholesterolemia
DSE-HCL-01-19-EU NCT04271280 Tabulated Results
(CT.gov)
Observational Study N/A Tenosynovial Giant
Cell Tumors
DS-ONC-01-15-EU NCT02948088 Tabulated Results
(CT.gov)
Observational Study N/A Gastric Cancer; Gastroesophageal Junction Cancer; Colorectal Cancer DS-Screen jRCT1080223325
JapicCTI-163380
Observational Study N/A Nonhemorrhagic Ischemic Stroke ASBI 801 NCT01496885 Tabulated Results
(CT.gov)
Observational Study N/A Healthy Subjects (Measure of Tidal Breathing) N/A jRCT1080223039
JapicCTI-153093
Observational Study N/A Venous Thromboembolism DSE-VTE-01-12 DRKS00004795

P

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Patritumab Deruxtecan
(U3-1402)
Advanced Solid Tumor; Melanoma; Head and Neck Cancer; Gastric Cancer HERTHENA-PanTumor01
U31402-277
NCT06172478
jRCT2031230575
Patritumab Deruxtecan
(U3-1402)
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer U31402-0001-EAP-MA NCT06099639
Patritumab Deruxtecan
(U3-1402)
Non-small Cell Lung Cancer HERTHENA-Lung02
U31402-A-U301
NCT05338970
2021-005879-40
jRCT2021220002
Patritumab Deruxtecan
(U3-1402)
Non-small Cell Lung Cancer U31402-A-U103 NCT04676477
jRCT2031200247
Patritumab Deruxtecan
(U3-1402)
Non-small Cell Lung Cancer HERTHENA-Lung01
U31402-A-U201
NCT04619004
2020-000730-17
jRCT2031200186
Patritumab Deruxtecan
(U3-1402)
Colorectal Cancer U31402-A-U202 NCT04479436
2019-004418-32
jRCT2031200139
Tabulated Results
(EU-CTIS)
Patritumab Deruxtecan
(U3-1402)
Non-small Cell Lung Cancer U31402-A-U102 NCT03260491
2017-000543-41
jRCT2080224788
JapicCTI-194868
Patritumab Deruxtecan
(U3-1402)
Breast Cancer U31402-A-J101 NCT02980341
jRCT2080223346
JapicCTI-163401
Pexidartinib TURALIO® Tenosynovial Giant Cell Tumor PL3397-A-J304 NCT04703322
jRCT2041200074
Pexidartinib TURALIO®️ Tenosynovial Giant Cell Tumor PL3397-A-U401 NCT04635111
Pexidartinib TURALIO®️ Tenosynovial Giant Cell Tumor PL3397-A-A303 NCT04488822 Tabulated Results
(CT.gov)
Pexidartinib TURALIO®️ Moderate Hepatic Impairment PL3397-A-U129 NCT04223635 Tabulated Results
(CT.gov)
Pexidartinib TURALIO®️ Tenosynovial Giant Cell Tumor; KIT-mutant Tumor; Other Solid Cancer PL3397-A-U126 NCT03291288 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Advanced Solid Cancer PL3397-A-A103 NCT02734433 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Melanoma; Non-small Cell Lung Cancer; Head and Neck Cancer; Gastrointestinal Stromal Tumor (GIST); Ovarian Cancer PLX108-14 NCT02452424 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Melanoma PLX108-13 NCT02975700 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Pigmented Villonodular Synovitis; Giant Cell Tumor of the Tendon Sheath PLX108-10 NCT02371369
2014-000148-14
Tabulated Results
(CT.gov)
(EU-CTIS)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Melanoma PLX108-09 NCT01826448 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Glioblastoma PLX108-08 NCT01790503 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Solid Cancer PLX108-07 NCT01525602 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Prostate Cancer PLX108-06 NCT01499043 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Acute Myeloid Leukemia PLX108-05 NCT01349049 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Glioblastoma PLX108-04 NCT01349036 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Hodgkin Lymphoma PLX108-03 NCT01217229 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Solid Cancer PLX108-01 NCT01004861 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Pexidartinib TURALIO®️ Healthy Subjects PL3397-A-U128 NCT03901313 Tabulated Results
(CT.gov)
Pexidartinib TURALIO®️ Healthy Subjects PL3397-A-U122 NCT03138759 Plain Language Summary
(EN)
Prasugrel EFFIENT® Acute Coronary Syndrome CS747S-B-A4003 NCT03672097 Tabulated Results
(CT.gov)
Prasugrel EFFIENT® Thrombotic Stroke CS0747S-A-J305 jRCT2080224080
JapicCTI-184141
Summary Results
(jRCT)
Prasugrel EFFIENT® Cerebrovascular Accident CS0747S-A-J304 jRCT2080221856
JapicCTI-121901
Summary Results
(jRCT)
Prasugrel EFFIENT® Cerebrovascular Accident CS0747S-A-J303 jRCT2080221542
JapicCTI-111582
Summary Results
(jRCT)
Prasugrel EFFIENT® Coronary Artery Disease CS0747S-B-J302 jRCT2080221511
JapicCTI-111550
Prasugrel EFFIENT® Acute Coronary Syndrome CS0747S-B-J301 jRCT2080221302
JapicCTI-101339
Prasugrel EFFIENT® Stroke CS0747S-A-J203 jRCT2080221011
JapicCTI-101044
Summary Results
(jRCT)
Prasugrel EFFIENT® Coronary Artery Disease CS747S-B-U4003 NCT01587651
2011-004064-29
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Prasugrel EFFIENT® Coronary Artery Disease CS747S-B-U4002 NCT01260584 Tabulated Results
(CT.gov)
Prasugrel EFFIENT® Coronary Artery Disease CS747S-B-U4001 NCT01014624 Tabulated Results
(CT.gov)
Perflubutane SONAZOID® Prostate Cancer DD723-B-J301 jRCT2080221271
JapicCTI-101308
Summary Results
(jRCT)
Perflubutane SONAZOID® Breast Cancer DD723-B-J302 jRCT2080221250
JapicCTI-101287
Perflubutane SONAZOID® Prostate Cancer DD723-B-J201 jRCT2080220862
JapicCTI-090893
Summary Results
(jRCT)
Perflubutane SONAZOID® Breast Cancer DD723-B-J202 jRCT2080220863
JapicCTI-090894
Pravastatin MEVALOTIN® Dyslipidemia MVT-OS-21-01 NCT05120895
Pravastatin MEVALOTIN® Dyslipidemia Associated With Type 2 Diabetes Mellitus MVT-OS-15-01 NCT05107063
Pravastatin MEVALOTIN® Hyperlipidemia APPROACH-J jRCT1080220524
JapicCTI-080534
Pactimibe Discontinued Atherosclerosis; Heterozygous Familial Hyper-cholesterolemia 505-205 NCT00151788
Pactimibe Discontinued Coronary Artery Disease 505-202 NCT00185042
Pactimibe Discontinued Atherosclerosis SE-505/14 NCT00185146
Patritumab Discontinued Head and Neck Cancer U31287-A-U203 NCT02633800
2015-002222-40
Tabulated Results
(EU-CTIS)
Patritumab Discontinued Lung Cancer U31287-A-J107 jRCT2080222789
JapicCTI-152841
Patritumab Discontinued Head and Neck Cancer U31287-A-U106 NCT02350712
2014-002445-22
Patritumab Discontinued Lung Cancer; Non-small Cell Lung Cancer U31287-A-U301 NCT02134015
2013-004371-12
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Patritumab Discontinued Solid Cancer U31287-A-U105 NCT01957280
Patritumab Discontinued Metastatic Breast Cancer U3-1287-A-U202 NCT01512199
Patritumab Discontinued Lung Cancer U31287-A-U201 NCT01211483
2010-021082-74
Tabulated Results
(CT.gov)
(EU-CTIS)
Patritumab Discontinued Non-small Cell Lung Cancer U31287-A-U201E 2013-000104-42 Tabulated Results
(EU-CTIS)
Patritumab Discontinued Breast Cancer U31287-A-J103 jRCT2080221730
JapicCTI-121772
Patritumab Discontinued Lung Cancer U31287-A-J102 jRCT2080221467
JapicCTI-111506
Patritumab Discontinued Solid Cancer U31287-A-J101 jRCT2080221225
JapicCTI-101262
Piclozotan Discontinued Parkinson's Disease ASBI-501 NCT00623363 Tabulated Results
(CT.gov)
Piclozotan Discontinued Acute Ischemic Stroke SPI-103 NCT00272909
2004-002437-39
Summary Results
(EU-CTIS)

Q

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Quizartinib VANFLYTA® Acute Myeloid Leukemia AC220-A-U202 NCT03793478
Quizartinib VANFLYTA® Acute Myeloid Leukemia AC220-A-A103 NCT03723681
Quizartinib VANFLYTA® Acute Myeloid Leukemia; Leukemia AC220-A-U302 NCT02668653
2015-004856-24
jRCT2080223611
JapicCTI-173667
Tabulated Results
(CT.gov)
(EU-CTIS)
Quizartinib VANFLYTA® Acute Myeloid Leukemia AC220-A-J201 NCT02984995
jRCT2080223386
JapicCTI-163441
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Plain Language Summary
(EN) (JP)
Quizartinib VANFLYTA® Acute Myeloid Leukemia AC220-A-J102 NCT02834390
jRCT2080223254
JapicCTI-163309
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Plain Language Summary
(EN) (JP)
Quizartinib VANFLYTA® Relapsed or Refactory Acute Myeloid Leukemia AC220-A-J101 NCT02675478
jRCT2080223088
JapicCTI-163142
Summary Results
(jRCT)
Plain Language Summary
(EN) (JP)
Quizartinib VANFLYTA® Acute Myeloid Leukemia AC220-007 NCT02039726
2013-004890-28
Tabulated Results
(CT.gov)
(EU-CTIS)
Plain Language Summary
(EN)
Quizartinib VANFLYTA® Acute Myeloid Leukemia 2689-CL-2004 NCT01565668
2011-005408-13
Tabulated Results
(CT.gov)
(EU-CTIS)
Plain Language Summary
(EN)
Quizartinib VANFLYTA® Acute Myeloid Leukemia 2689-CL-0011 NCT01468467 Plain Language Summary
(EN)
Quizartinib VANFLYTA® Acute Myeloid Leukemia 2689-CL-0005 NCT01390337 Plain Language Summary
(EN)
Quizartinib VANFLYTA® Solid Cancer AC220-004 NCT01049893 Plain Language Summary
(EN)
Quizartinib VANFLYTA® Acute Myeloid Leukemia AC220-002 NCT00989261
2009-013093-41
Tabulated Results
(CT.gov)
(EU-CTIS)
Plain Language Summary
(EN)
Quizartinib VANFLYTA® Acute Myeloid Leukemia CP0001 NCT00462761 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Quizartinib VANFLYTA® Moderate Hepatic Impairment AC220-A-U105 NCT04473664 Tabulated Results
(CT.gov)
Quizartinib VANFLYTA® Healthy Subjects AC220-A-U107 NCT04796831 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Quizartinib VANFLYTA® Healthy Subjects AC220-A-U106 NCT04459598 Tabulated Results
(CT.gov)
Quizartinib VANFLYTA® Healthy Subjects AC220-A-U104 NCT04459585 Tabulated Results
(CT.gov)
Quizartinib VANFLYTA® Healthy Subjects; Liver Disease AC220-016 Plain Language Summary
(EN)
Quizartinib VANFLYTA® Healthy Subjects AC220-015 Plain Language Summary
(EN)
Quizartinib VANFLYTA® Healthy Subjects AC220-014 Plain Language Summary
(EN)
Quizartinib VANFLYTA® Healthy Subjects AC220-012 Plain Language Summary
(EN)
Quizartinib VANFLYTA® Healthy Subjects AC220-008 Plain Language Summary
(EN)
Quizartinib VANFLYTA® Healthy Subjects AC220-006 Plain Language Summary
(EN)

R

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Raludotatug Deruxtecan
(DS-6000)
Solid Cancer REJOICE-Ovarian01
DS6000-109
NCT06161025
jRCT2031230556
Raludotatug Deruxtecan
(DS-6000)
Renal Cancer; Ovarian Cancer DS6000-A-U101 NCT04707248
jRCT2031220075
RS Virus Vaccine
(VN-0200)
Prevention of Respiratory Syncytial Virus Infection VN0200-091 NCT05547087
jRCT2071220051
RS Virus Vaccine
(VN-0200)
Prevention of Respiratory Syncytial Virus Infection VN0200-A-J101 NCT04914520
jRCT2031210069
Rifampicin RIFADIN® Healthy Subjects RIFADI-A-J101 jRCT1080223619
JapicCTI-173675
Renadirsen Discontinued Duchenne Muscular Dystrophy DS5141-A-J201 NCT04433234
jRCT2080225225
JapicCTI-205321
Renadirsen Discontinued Duchenne Muscular Dystrophy DS5141-A-J101 NCT02667483
jRCT2080223018
JapicCTI-153072
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS011-A-U302 NCT00571519 Tabulated Results
(CT.gov)
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS0011-203 NCT00143520
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS0011-A-U301 NCT00484198
2006-005047-28
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS011-A-J204 NCT00575471
jRCT1080223619
JapicCTI-070424
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS011-A-J205 NCT00575874
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS0011-A-U302 2007-005263-97 Summary Results
(EU-CTIS)

S

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Sitafloxacin GRACEVIT® COPD Exacerbation Acute DSCN-GRV AECOPD-CSIS-001 NCT05400369
Sitafloxacin GRACEVIT® Infections DU6859-A-J301 jRCT2080220704
JapicCTI-090731
Summary Results
(jRCT)
Sitafloxacin GRACEVIT® Infections DU6859a-49 jRCT2080220062
JapicCTI-050062
Sitafloxacin GRACEVIT® Infections DU6859a-48 jRCT2080220064
JapicCTI-050064
Sitafloxacin GRACEVIT® Infections DU6859a-47 jRCT2080220065
JapicCTI-050065
Sitafloxacin GRACEVIT® Infections DU6859a-46 jRCT2080220069
JapicCTI-050069
Sitafloxacin GRACEVIT® Infections DU6859a-45 jRCT2080220066
JapicCTI-050066
Sitafloxacin GRACEVIT® Infections DU6859a-44 jRCT2080220067
JapicCTI-050067
Sitafloxacin GRACEVIT® Infections DU6859a-43 jRCT2080220063
JapicCTI-050063
Sitafloxacin GRACEVIT® Infections DU6859a-42 jRCT2080220068
JapicCTI-050068
Soblidotin Discontinued Soft Tissue Sarcoma CDR0000310138 NCT00064220
Soblidotin Discontinued Non-small Cell Lung Cancer CDR0000301749 NCT00061854
SUN13834 Discontinued Atopic Dermatitis ASBI 404 NCT00717769
SUN13837 Discontinued Acute Spinal Cord Injury ASBI 603 NCT01502631
2012-004373-80
Tabulated Results
(CT.gov)
(EU-CTIS)
SUN13837 Discontinued Stroke ASBI 802 NCT02258880
Sodium Hyaluronate N/A Hip Osteoarthritis ADA 2003-01 NCT00330135
Spironolactone N/A Diabetes N/A jRCT1080222094
JapicCTI-132140

T

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Solid Tumors ROMast-001 NCT06174987
jRCT2031230379
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer
(Observational )
DS8201-0005-CIS-MA NCT05945732
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast15
DS8201-0001-CIS-MA
NCT05950945
2023-505616-38
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Non-small Cell Lung Cancer ENH-DS-22004 jRCT2071220096
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Colorectal Cancer DESTINY-CRC02
DS8201-A-U207
NCT04744831
2020-004782-39
jRCT2051200124
Tabulated Results
(CT.gov)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer; Gastroesophageal Junction Adenocarcinoma DESTINY-Gastric04
DS8201-A-U306
NCT04704934
2020-004559-34
jRCT2031200369
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Non-small Cell Lung Cancer DESTINY-Lung02
DS8201-A-U206
NCT04644237
2020-003427-42
jRCT2061200038
Tabulated Results
(CT.gov)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast05
DS8201-A-U305
NCT04622319
2020-003982-20
jRCT2061200033
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer; Non-small Cell Lung Cancer DS8201-A-U106 NCT04042701
2018-002489-38
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer DESTINY-Gastric02
DS8201-A-U205
NCT04014075
2019-001512-34
Tabulated Results
(CT.gov)
(EU-CTIS)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast04
DS8201-A-U303
NCT03734029
2018-003069-33
jRCT2080224162
JapicCTI-184223
Tabulated Results
(CT.gov)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast03
DS8201-A-U302
NCT03529110
2018-000222-61
jRCT2080223919
JapicCTI-183976
Tabulated Results
(CT.gov)
(EU-CTIS)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast02
DS8201-A-U301
NCT03523585
2018-000221-31
jRCT2080223959
JapicCTI-184017
Tabulated Results
(CT.gov)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer; Urothelial Cancer DS8201-A-U105 NCT03523572
2018-000371-32
Tabulated Results
(CT.gov)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Non-small Cell Lung Cancer DESTINY-Lung01
DS8201-A-U204
NCT03505710
2017-004781-94
jRCT2080223860
JapicCTI-183916
Tabulated Results
(CT.gov)
(EU-CTIS)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Colorectal Cancer DESTINY-CRC01
DS8201-A-J203
NCT03384940
2017-003466-28
jRCT2080223752
JapicCTI-173808
Tabulated Results
(CT.gov)
(EU-CTIS)
Summary Results
(jRCT)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Neoplasm Metastasis DS8201-A-A104 NCT03383692
jRCT2080223734
JapicCTI-173790
Tabulated Results
(CT.gov)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer; Breast Cancer DS8201-A-A103 NCT03368196 Tabulated Results
(CT.gov)
Plain Language Summary
(EN)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DS8201-A-J102 NCT03366428
jRCT2080223735
JapicCTI-173791
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Plain Language Summary
(EN) (JP)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer; Gastroesophageal Junction Adenocarcinoma DS8201-C-J4001 jRCT2080225138
JapicCTI-205234
Summary Results
(jRCT)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer; Gastroesophageal Junction Adenocarcinoma DESTINY-Gastric01
DS8201-A-J202
NCT03329690
jRCT2080223671
JapicCTI-173727
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast01
DS8201-A-U201
NCT03248492
2016-004986-18
jRCT2080223637
JapicCTI-173693
Tabulated Results
(CT.gov)
(EU-CTIS)
Plain Language Summary
(EN) (JP)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Advanced Solid Malignant Tumors DS8201-A-J101 NCT02564900
jRCT2080222926
JapicCTI-152978
Tabulated Results
(CT.gov)
Plain Language Summary
(EN) (JP)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® HER2-positive Breast Cancer EUROPA T-DXd
DS8201-0002-EAP-MA
NCT05458401
Tetravalent Combination Vaccine SQUAREKIDS Prevention of Pertussis; Diphtheria; Tetanus; Poliomyelitis Infection DD687-A-J301 jRCT2080221313
JapicCTI-101350
Summary Results
(jRCT)
Tetravalent Combination Vaccine SQUAREKIDS Prevention of Pertussis; Diphtheria; Tetanus; Poliomyelitis Infection DD687-A-J201 jRCT2080220899
JapicCTI-090931
Summary Results
(jRCT)
Tigatuzumab Discontinued Liver Cancer CS1008-A-U204 NCT01033240
jRCT2080221104
JapicCTI-101138
Tigatuzumab Discontinued Metastatic Colorectal Cancer CS1008-A-U105 NCT01124630
Tigatuzumab Discontinued Ovarian Cancer CS1008-A-U205 NCT00945191 Tabulated Results
(CT.gov)
Tigatuzumab Discontinued Non-small Cell Lung Cancer CS1008-A-E202 NCT00991796
2007-004574-11
Summary Results
(EU-CTIS)
Tigatuzumab Discontinued Colorectal Cancer CS1008-A-E203 NCT00969033
2007-005675-34
Summary Results
(EU-CTIS)
Tigatuzumab Discontinued Pancreatic Cancer CS1008-A-U201 NCT00521404 Tabulated Results
(CT.gov)
Tigatuzumab Discontinued Solid Cancer; Lymphomas CS1008-A-U101 NCT00320827
Tigatuzumab Discontinued Solid Cancer CS1008-A-J104 jRCT2080220861
JapicCTI-090892
Tivantinib Discontinued Inoperable Hepatocellular Carcinoma ARQ197-A-U303 NCT01755767
2012-003308-10
Tabulated Results
(CT.gov)
(EU-CTIS)
Tivantinib Discontinued Non-squamous, Non-small Cell Lung Cancer ARQ197-A-U302 NCT01244191
2010-022365-10
Tivantinib Discontinued Solid Cancer; Hepatic Impairment ARQ197-A-U160 NCT02150733
Tivantinib Discontinued Colorectal Cancer ARQ197-A-U252 NCT01075048
2009-016025-34
Tabulated Results
(CT.gov)
(EU-CTIS)
Tivantinib Discontinued Solid Cancer ARQ197-A-U158 NCT01517399
Tivantinib Discontinued Cancer ARQ197-A-U159 NCT01699061
Tivantinib Discontinued Non-CNS Germ Cell Tumors ARQ197-A-U251 NCT01055067
2009-015400-26
Tabulated Results
(CT.gov)
Summary Results
(EU-CTIS)
Tivantinib Discontinued Solid Cancer ARQ197-A-U157 NCT01149720

U

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
U3-1565 Discontinued Advanced Solid Malignant Tumors; Advanced Ovarian Cancer U31565-A-U101 NCT01290471
U3-1565 Discontinued Solid Cancer U31565-A-J102 jRCT2080221445
JapicCTI-111484
U3-1784 Discontinued Advanced Solid Cancer; Hepatocellular Cancer U31784-A-E101 NCT02690350

V

Generic Name / Project Code Trade Name Medical
Condition
Study Number Study Protocol Results and
Plain Language Summaries
Valemetostat
(DS-3201)
EZHARMIA® Solid Tumors; Gastric Cancer; Gastroesophageal Junction Cancer; Non-small Cell Lung Cancer DS3201-324 NCT06244485
jRCT2031230614
Valemetostat
(DS-3201)
EZHARMIA® Peripheral T-Cell Lymphoma, Adult T-Cell Leukemia/
Lymphoma
DS3201-A-U202 NCT04703192
jRCT2071200095
Valemetostat
(DS-3201)
EZHARMIA® Hepatic Impairment DS3201-A-U106 NCT04276662
Valemetostat
(DS-3201)
EZHARMIA® Adult T-cell Leukemia/
Lymphoma
DS3201-A-J201 NCT04102150
jRCT2080224880
JapicCTI-194964
Valemetostat
(DS-3201)
EZHARMIA® Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia DS3201-A-U102 NCT03110354 Tabulated Results
(CT.gov)
Valemetostat
(DS-3201)
EZHARMIA® Non-hodgkin Lymphoma DS3201-A-J101 NCT02732275
jRCT2080223118
JapicCTI-163173
Valemetostat
(DS-3201)
EZHARMIA® Healthy Subjects DS3201-A-J109 jRCT2071200043
Valemetostat
(DS-3201)
EZHARMIA® Healthy Subjects DS3201-A-J107 jRCT2080225242
JapicCTI-205338
Valemetostat
(DS-3201)
EZHARMIA® Healthy Subjects DS3201-A-J104 jRCT2080223846
JapicCTI-183902
Valemetostat
(DS-3201)
EZHARMIA® Healthy Subjects DS3201-A-J103 jRCT2080223748
JapicCTI-173804